Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A2 | O95436 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 4/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | WDR5 | P61964 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15444460 | 0.94 | SLC34A2 (0.43) | SLC34A2KDM1AHDAC1ROCK2ROCK1 | |
| SCHEMBL46992 | 0.92 | SLC34A2 (0.51) | SLC34A2MAPK14LCKKDRGAA | |
| SCHEMBL46994 | 0.88 | SLC34A2 (0.52) | SLC34A2KDM1AHDAC1MAPK14LCK | |
| SCHEMBL15444421 | 0.86 | KDM1A (0.42) | SLC34A2KDM1AHDAC1ROCK2ROCK1 | |
| SCHEMBL15444468 | 0.86 | KDM1A (0.42) | SLC34A2KDM1AHDAC1ROCK2ROCK1 | |
| SCHEMBL46988 | 0.85 | SLC34A2 (0.53) | SLC34A2KDM1AHDAC1MAPK14LCK | |
| SCHEMBL16808359 | 0.85 | KDM1A (0.41) | SLC34A2KDM1AHDAC1ROCK2ROCK1 | |
| SCHEMBL46512 | 0.85 | SLC34A2 (0.56) | SLC34A2KDM1AHDAC1MAPK14LCK | |
| SCHEMBL15432551 | 0.85 | SLC34A2 (0.59) | SLC34A2KDM1AHDAC1MAPK14LCK | |
| SCHEMBL16808343 | 0.85 | KDM1A (0.39) | SLC34A2KDM1AHDAC1ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2017-02-09 | — | — | US | disclosed |
| US-8916569-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2014-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A2, SLC34A1, SLC10A2 | SLC34A2 1/4885KDM1A 4426/4885HDAC1 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.